{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:38:55Z","timestamp":1791077935582,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.bbrc.2008.05.090","type":"journal-article","created":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T16:53:29Z","timestamp":1211993609000},"page":"503-507","source":"Crossref","is-referenced-by-count":24,"title":["Biliverdin is the endogenous ligand of human serum \u03b11-acid glycoprotein"],"prefix":"10.1016","volume":"372","author":[{"given":"Ferenc","family":"Zsila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"M\u00e1dy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2008.05.090_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0167-4838(00)00153-9","article-title":"Alpha-1-acid glycoprotein","volume":"1482","author":"Fournier","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2008.05.090_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/138920307779941497","article-title":"The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases","volume":"8","author":"Ceciliani","year":"2007","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.bbrc.2008.05.090_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1359-6101(02)00054-0","article-title":"Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties","volume":"14","author":"Hochepied","year":"2003","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bbrc.2008.05.090_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF00210681","article-title":"Use of transgenic mice for the characterization of human alpha1-acid glycoprotein (orosomucoid) variants","volume":"84","author":"Tomei","year":"1989","journal-title":"Hum. Genet."},{"key":"10.1016\/j.bbrc.2008.05.090_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/mol.54.1.129","article-title":"Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure\u2013activity relationship model for drug binding to the A variant","volume":"54","author":"Herve","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2008.05.090_bib6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0009-8981(91)90312-Z","article-title":"Variations in relative concentrations of variants of human alpha 1-acid glycoprotein after acute-phase conditions","volume":"203","author":"Eap","year":"1991","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bbrc.2008.05.090_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbapap.2005.12.006","article-title":"Comparative ligand-binding analysis of ten human lipocalins","volume":"1764","author":"Breustedt","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2008.05.090_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-4838(00)00148-5","article-title":"The lipocalin protein family: structural and sequence overview","volume":"1482","author":"Flower","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2008.05.090_bib9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0167-4838(00)00147-3","article-title":"Experimentally determined lipocalin structures","volume":"1482","author":"Flower","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2008.05.090_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1081\/DMR-100104402","article-title":"Human alpha-1-glycoprotein and its interactions with drugs","volume":"33","author":"Israili","year":"2001","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bbrc.2008.05.090_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clpt.2006.06.006","article-title":"Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation","volume":"80","author":"Colombo","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2008.05.090_bib12","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0006-2952(03)00469-6","article-title":"Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo","volume":"66","author":"Larghero","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2008.05.090_bib13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/0091270005274549","article-title":"Review of UCN-01 development: a lesson in the importance of clinical pharmacology","volume":"45","author":"Fuse","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2008.05.090_bib14","doi-asserted-by":"crossref","first-page":"19595","DOI":"10.1073\/pnas.0709681104","article-title":"Acute-phase protein alpha-1-acid glycoprotein mediates neutrophil migration failure in sepsis by a nitric oxide-dependent mechanism","volume":"104","author":"Mestriner","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2008.05.090_bib15","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1248\/bpb.30.1226","article-title":"Alpha1-acid glycoprotein suppresses rat acute inflammatory paw edema through the inhibition of neutrophils activation and prostaglandin E2 generation","volume":"30","author":"Matsumoto","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bbrc.2008.05.090_bib16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10517-007-0283-8","article-title":"Effects of alpha(1)-acid glycoprotein on hemostasis in experimental septic peritonitis","volume":"144","author":"Osikov","year":"2007","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.bbrc.2008.05.090_bib17","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/01.TP.0000138096.14126.CA","article-title":"Exogenous alpha-1-acid glycoprotein protects against renal ischemia\u2013reperfusion injury by inhibition of inflammation and apoptosis","volume":"78","author":"de Vries","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.bbrc.2008.05.090_bib18","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S1386-1425(99)00147-X","article-title":"New insights in the conformation of alpha(1)-acid glycoprotein (orosomucoid). Quenching resolved emission anisotropy studies","volume":"55","author":"Albani","year":"1999","journal-title":"Spectrochim. Acta A"},{"key":"10.1016\/j.bbrc.2008.05.090_bib19","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1016\/0006-2952(87)90009-8","article-title":"Binding of catecholamines to alpha-1 acid glycoprotein, albumin and lipoproteins in human serum","volume":"36","author":"Sager","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2008.05.090_bib20","doi-asserted-by":"crossref","first-page":"14021","DOI":"10.1021\/bi061657l","article-title":"Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine","volume":"45","author":"Ojala","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2008.05.090_bib21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.carres.2003.10.016","article-title":"Tertiary structure of human alpha1-acid glycoprotein (orosomucoid). Straightforward fluorescence experiments revealing the presence of a binding pocket","volume":"339","author":"Albani","year":"2004","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.bbrc.2008.05.090_bib22","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.bbagen.2006.08.015","article-title":"Selective binding of imatinib to the genetic variants of human \u03b11-acid glycoprotein","volume":"1760","author":"Fitos","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2008.05.090_bib23","unstructured":"H.B. Halsall, R.C. Austin, J.L. Dage, H. Sun, K.T. Schlueter, Structural aspects of \u03b11-acid glycoprotein and its interactions, in: M. Otagiri, Y. Sugiyama, B. Testa, J.P. Tillement (Eds.), Basic Sciences to Clinical Applications, Scientific Commitee of International Symposium on Serum Albumin and \u03b11-Acid Glycoprotein, Kumamoto, Japan, 2000, pp. 45\u201354."},{"key":"10.1016\/j.bbrc.2008.05.090_bib24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0006-2952(02)01521-6","article-title":"Probing the binding of the flavonoid, quercetin to human serum albumin by circular dichroism, electronic absorption spectroscopy and molecular modelling methods","volume":"65","author":"Zsila","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2008.05.090_bib25","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1248\/bpb.30.1593","article-title":"Selective binding of tamsulosin to genetic variants of human alpha1-acid glycoprotein","volume":"30","author":"Hanada","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bbrc.2008.05.090_bib26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.bcp.2003.09.039","article-title":"Specific ligand binding on genetic variants of human \u03b11-acid glycoprotein studied by circular dichroism spectroscopy","volume":"67","author":"Fitos","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2008.05.090_bib27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0957-4166(99)00037-3","article-title":"Optical activity and stereochemistry of linear oligopyrroles and bile pigments","volume":"10","author":"Boiadjiev","year":"1999","journal-title":"Tetrahedron: Asymmetry"},{"key":"10.1016\/j.bbrc.2008.05.090_bib28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0022-2836(87)90296-8","article-title":"Molecular structure of the bilin binding protein (BBP) from Pieris brassicae after refinement at 2.0\u01fa resolution","volume":"198","author":"Huber","year":"1987","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbrc.2008.05.090_bib29","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.bbagen.2007.01.009","article-title":"The drug binding site of human \u03b11-acid glycoprotein: insight from induced circular dichroism and electronic absorption spectra","volume":"1770","author":"Zsila","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2008.05.090_bib30","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.bmc.2005.10.045","article-title":"Selective binding of coumarin enantiomers to human \u03b11-acid glycoprotein genetic variants","volume":"14","author":"Hazai","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrc.2008.05.090_bib31","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1016\/S0021-9258(18)61878-2","article-title":"The amino acid substitutions found in the genetic variants of alpah1-acid glycoprotein","volume":"246","author":"Nimberg","year":"1971","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2008.05.090_bib32","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.bbagen.2006.04.006","article-title":"Multiple ligand-binding properties of the lipocalin member chicken \u03b11-acid glycoprotein studied by circular dichroism and electronic absorption spectroscopy: the essential role of the conserved tryptophan residue","volume":"1760","author":"Zsila","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbrc.2008.05.090_bib33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2125.1993.tb04224.x","article-title":"Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein","volume":"36","author":"Herve","year":"1993","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbrc.2008.05.090_bib34","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2174\/138955707781024517","article-title":"Heme oxygenase-1: a fundamental guardian against oxidative tissue injuries in acute inflammation","volume":"7","author":"Takahashi","year":"2007","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bbrc.2008.05.090_bib35","first-page":"38","article-title":"Biliverdin reductase: new features of an old enzyme and its potential therapeutic significance","volume":"60","author":"Florczyk","year":"2008","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bbrc.2008.05.090_bib36","doi-asserted-by":"crossref","first-page":"G695","DOI":"10.1152\/ajpgi.00152.2005","article-title":"Biliverdin protects against polymicrobial sepsis by modulating inflammatory mediators","volume":"290","author":"Overhaus","year":"2006","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbrc.2008.05.090_bib37","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1089\/ars.2007.1807","article-title":"Therapeutic applications of bilirubin and biliverdin in transplantation","volume":"9","author":"\u00d6llinger","year":"2007","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bbrc.2008.05.090_bib38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.mrrev.2007.05.001","article-title":"The anti-mutagenic properties of bile pigments","volume":"658","author":"Bulmer","year":"2008","journal-title":"Mutat. Res."},{"key":"10.1016\/j.bbrc.2008.05.090_bib39","doi-asserted-by":"crossref","first-page":"F563","DOI":"10.1152\/ajprenal.00220.2005","article-title":"Products of heme oxygenase and their potential therapeutic applications","volume":"290","author":"Kirkby","year":"2006","journal-title":"Am. J. Physiol. Renal. Physiol."},{"key":"10.1016\/j.bbrc.2008.05.090_bib40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1124\/pr.107.07104","article-title":"Pharmacological and clinical aspects of heme oxygenase","volume":"60","author":"Abraham","year":"2008","journal-title":"Pharmacol. Rev."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X08010115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X08010115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T07:00:38Z","timestamp":1631343638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X08010115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0006291X08010115"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2008.05.090","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}